奥雷巴替尼联合奥加伊妥珠单抗治疗多次复发Ph阳性急性淋巴细胞白血病1例
收稿日期: 2025-02-19
网络出版日期: 2026-04-08
基金资助
兰州市青年科技人才创新项目(2023-QN-16);甘肃省重点研发计划(22YF7FA106);联勤保障部队第九四〇医院血液病医学研究中心项目(2021yxky078);甘肃省科技计划项目(21JR7RA015);甘肃省科技计划项目(22YF7FA106);甘肃省科技计划项目(23JRRA535);甘肃省科技计划项目(25JRRA1184)
版权
Olverembatinib combined with inotuzumab ozogamicin in Philadelphia chromosome-positive acute lymphoblastic leukemia with multiple relapses: a case report
Received date: 2025-02-19
Online published: 2026-04-08
Copyright
复发/难治性（relapsed/refractory, R/R）费城染色体阳性急性淋巴细胞白血病（Philadelphia chromosome-positive acute lymphoblastic leukemia, Ph+ ALL）治疗困难，预后差，总生存期较短。酪氨酸激酶抑制剂（tyrosine kinase inhibitor，TKI）及免疫治疗为此类患者带来了新的治愈希望。本文回顾性分析1例多次复发的Ph+ ALL患者，经奥雷巴替尼联合减量奥加伊妥珠单抗治疗，2个月后复查达完全缓解（complete response, CR），微小残留病灶（minimal residual disease, MRD）阴性，基本达完全分子学缓解（complete molecular response, CMR），以期为临床提供治疗经验。
关键词： 奥雷巴替尼; 奥加伊妥珠单抗; 复发难治; 费城染色体阳性急性淋巴细胞白血病
刘恒 , 葸瑞 , 潘耀柱 , 王宗慧 , 田红娟 , 毛东锋 , 吴涛 . 奥雷巴替尼联合奥加伊妥珠单抗治疗多次复发Ph阳性急性淋巴细胞白血病1例[J]. 内科理论与实践, 2026 , 21(01) : 59 -61 . DOI: 10.16138/j.1673-6087.2026.01.08
Relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is difficult to treat, facing a poor prognosis and short overall survival. The usage of tyrosine kinase inhibitor (TKI) and immunotherapy has brought new hope for the treatment of R/R Ph+ ALL for patients. This paper retrospectively analyzed a patient with Ph+ ALL experiencing multiple relapses, who was treated with olverembatinib in combination with a reduced dose of inotuzumab ozogamicin. The patient achieved complete response (CR) and minimal residual disease (MRD) negativity upon reexamination two months later, attaining a near-complete molecular response (CMR). A review of relevant literature is included to provide clinical treatment experience.
| [1] | Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults[J]. Cancers (Basel), 2022, 14(7):1805. |
| [2] | Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia[J]. Blood, 2015, 125(24):3711-3719. |
| [3] | Jiang Q, Huang XJ, Chen Z, et al. Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase Ⅱ) trials[J]. Blood, 2020, 136(Suppl 1):50-51. |
| [4] | Jiang Q, Li ZR, Hou Y, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation[J]. Blood, 2022, 140(Suppl 1):203-204. |
| [5] | Jabbour E, Kantarjian HM, Koller PB, et al. Update of olverembatinib (HQP1351) overcoming ponatinib and/or asciminib resistance in patients (Pts) with heavily pretreated/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)[J]. Blood, 2023, 142(Suppl 1):1798 |
| [6] | Liang E, Min P, Xiong Y, et al. Olverembatinib (HQP1351) enhances antitumor effects of chemotherapy in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)[J]. Blood, 2023, 142(Suppl 1):5882 |
| [7] | Liu W, Wang C, Ouyang W, et al. Efficacy and safety of olverembatinib in adult BCR: : ABL1-positive ALL with T315I mutation or relapsed/refractory disease[J]. Br J Haematol, 2024, 205(6):2228-2233. |
| [8] | Zhu Y, Huang J, Wang Y, et al. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Ann Hematol, 2024, 103(11):4643-4648. |
| [9] | Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial[J]. J Hematol Oncol, 2022, 15(1):113. |
| [10] | 中国临床肿瘤学会(CSCO)白血病专家委员会. 奥加伊妥珠单抗治疗急性淋巴细胞白血病临床应用指导原则(2023年版)[J]. 白血病·淋巴瘤, 2023, 32(8):449-456. |
| Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO). Guideline principles for clinical application of inotuzumab ozogamicin in treatment of acute lymphoblastic leukemia (2023 version)[J]. J Leuk Lymphoma, 2023, 32(8):449-456. | |
| [11] | Short NJ, Jabbour E, Jain N, et al. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions[J]. J Hematol Oncol, 2024, 17(1):32. |
| [12] | Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375(8):740-753. |
| [13] | Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22[J]. Clin Cancer Res, 2021, 27(10):2742-2754. |
| [14] | Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review[J]. Bone Marrow Transplant, 2018, 53(4):449-456. |
/
| 〈 |
|
〉 |
